| --- | --- | --- | --- | |-------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | Better health for people, | | | | | Brighter future for the world | | | | Important Notice For the purposes of this notice, "presentation" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding this presentation. This presentation (including any ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q2 2022 Earnings Conference Call October 28, 2021 5:30 AM ET Company Participants Christopher OÂ'Reilly - Global Head, IR & Global Finance Christophe Weber - President and CEO Andy Plump - President Research and Development Costa Saroukos - CFO Masato Iwasaki - Japan General Affairs Ramona Sequeira - President, U.S. Business Unit and Global Portfolio Commercialization Julie Kim - President, Plasma-Derived Therapies Business Unit Conference Call Participants H ...

Takeda Pharmaceutical Co Ltd (NYSE:TAK) Q1 2022 Earnings Conference Call July 30, 2021 6:00 AM ET Company Participants Christopher O'Reilly - Global Head, IR & Global Finance Christophe Weber - President & CEO Andrew Plump - President, Research & Development Constantine Saroukos - CFO Masato Iwasaki - Representative Director Julie Kim - President, Plasma-Derived Therapies Business Unit Ramona Sequeira - President, US Business Unit & Global Portfolio Commercialization Conference Call Participants Hidemaru Ya ...

Better health for people, Brighter future for the world. FY2021 Q1 EARNINGS ANNOUNCEMENT July 30, 2021 IMPORTANT NOTICE For the purposes of this notice, "presentation" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding this presentation. This presentation (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does no ...

1 As filed with the Securities and Exchange Commission on June 29, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________ FORM 20-F ___________________________________________________________ ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2021 OR ☐ TRA ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q4 2020 Earnings Conference Call May 11, 2021 8:00 AM ET Company Participants Christopher O'Reilly - Global Head, IR Christophe Weber - President & CEO Andy Plump - President, R&D Costa Saroukos - CFO Ramona Sequeira - President, U.S. Business Unit & Global Portfolio Commercialization Julie Kim - President, Plasma-Derived Therapies Business Unit Conference Call Participants Shinichiro Muraoka - Morgan Stanley MUFG Ken Cacciatore - Cowen Hidemaru Yamaguchi - C ...

BETTER HEALTH FOR PEOPLE, BRIGHTER FUTURE FOR THE WORLD FY2020 Q4 Earnings Announcement May 11, 2021 Better Health, Brighter Future IMPORTANT NOTICE For the purposes of this notice, "presentation" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding this presentation. This presentation (including any oral briefing and any question-and-answer in connection with it) is ...

Pipeline Highlights - Takeda anticipates up to 6 New Molecular Entity (NME) regulatory submissions by the end of FY21, with the potential for 4 approvals[8] - Takeda expects 7 NMEs in pivotal studies across 10 indications by the end of FY21[8] - Takeda intends to increase R&D investment to 500-550 billion JPY in FY2021[8] - Takeda has 11 Wave 1 NMEs, with 5 programs having Breakthrough Therapy Designation (BTD), 3 with Fast Track Designation (FTD), and 1 with Sakigake designation[17] Maribavir (TAK-620) - Maribavir demonstrated superior viremia clearance compared to conventional therapies, with a treatment difference of 328% at Week 8 in the Phase 3 Resistant/Refractory CMV Infection Study[58] - Maribavir maintained superior viremia clearance and symptom control through Week 16, with a treatment difference of 95%[61] - Approximately 25% of transplant patients experience Cytomegalovirus (CMV) infections[74] Soticlestat (TAK-935) - In the ELEKTRA study, the combined Dravet Syndrome (DS) & Lennox-Gastaut Syndrome (LGS) populations achieved a statistically significant placebo-adjusted seizure reduction of -305% over the 12-week maintenance period[129] - The Dravet Syndrome cohort in the ELEKTRA study showed a statistically significant placebo-adjusted median seizure reduction of 46%[135] - Approximately 10,000 patients are diagnosed with Dravet Syndrome in the US and approximately 30,000-50,000 patients are diagnosed with Lennox-Gastaut Syndrome in the US[150] Orexin Franchise (TAK-994) - Takeda is on track for potential first approval of an Oral Orexin Agonist in Narcolepsy Type 1 (NT1) in FY2024[161] - In sleep deprived healthy volunteers, TAK-994 demonstrated statistically significant improvements in the objective (MWT) and subjective (KSS) measures of wakefulness[203] - Approximately 30-50% of adult NT1 patients are estimated to be diagnosed in developed countries[224]

TAKEDA ONCOLOGY 2020 World Conference on Lung Cancer IR Event January 29, 2021 IMPORTANT NOTICE 2 For the purposes of this notice, "presentation" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding this release. This presentation (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or ...

Takeda Pharmaceutical Co Ltd (NYSE:TAK) Q3 2021 Earnings Conference Call February 4, 2021 6:00 AM ET Company Participants Christopher O'Reilly - Global Head, IR & Global Finance Christophe Weber - President & CEO Andrew Plump - President, Research & Development and Director Constantine Saroukos - CFO & Director Masato Iwasaki - President, Japan Pharma Business Unit & Director Julie Kim - President, Plasma-Derived Therapies Business Unit Ramona Sequeira - President, US Business Unit & Global Portfolio Commer ...